Sep 27

Scientific

SS 02 - Escalate, De-escalate, or Substitute? Trials Shaping Prostate Cancer Care

03:00pm - 04:00pm ET

Genitourinary Cancer

MODERATOR(S)

Soumyajit Roy, MBBS, MSc. - University Hospitals Seidman Cancer Center

Seungtaek Choi, MD - MD Anderson Cancer Center - Proton Therapy Center

Credits

AMA PRA Category 1 Credits:

1.00

Rate This Session

Presentations

03:00pm - 03:10pm ET

Brachytherapy Versus External Beam Dose-Escalated Boost for Intermediate-Risk Prostate Cancer: Definitive Results of the GETUG P05 Trial

Speaker: Ariane Lapierre, MD, PhD - Hopital Lyon Sud, Pierre Benite
03:10pm - 03:20pm ET

Long-Term Follow-up Results for NRG/RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

Speaker: Daniel Krauss, MD, FASTRO - Beaumont Health, Royal Oak
03:20pm - 03:30pm ET

Co-Primary Endpoint Analysis for the INTREPId Randomized Trial of Prostate Radiation Therapy with Androgen Deprivation Therapy vs. Darolutamide Monotherapy

Speaker: Martin King, MD, PhD - Brigham and Women's Hopsital, Boston
03:30pm - 03:40pm ET

Three-Year Outcomes of a Prospective Randomized Trial of Moderately-Hypofractionated and Standard-Fractionated Proton Therapy in Prostate Cancer Embedded within COMPPARE Trial

Speaker: Nancy Mendenhall, MD, FASTRO - University of Florida Proton Therapy Institute, Jacksonville
03:40pm - 03:50pm ET

<em>I</em>ntermittent Androgen Deprivation Therapy with or without <em>St</em>ereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive <em>O</em>ligometastatic <em>P</em>rostate Cancer: A Randomized Study (i-STOP)

Speaker: Rachel Glicksman, MD - University of Toronto, Toronto
03:50pm - 04:00pm ET

Discussant

Speaker: Bridget Koontz, MD, FASTRO, FASTRO - AdventHealth Cancer Institute, Orlando